Osteoprotegerin, rank and rank ligand

被引:0
|
作者
Kurban, Sevil [1 ]
Mehmetoglu, Idris [1 ]
机构
[1] Selcuk Univ, Meram Tip Fak, Biyokimya Anabilim Dali, TR-42080 Konya, Turkey
关键词
osteoprotegerin; receptor activator of nuclear factor-kappa B; receptor activator of nuclear factor-kappa B ligand; Bone resorption; Immune system; Arterial calcification;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts, leading to bone resorption. Osteoprotegerin is a soluble decoy receptor for the receptor activator of nuclear factor-kappa B ligand thereby inhibiting bone resorption. In addition to providing fundamental insights in bone biology, they may be involved in the immune system, arterial calcification and a number of metabolic bone diseases. In this review, we summarize the roles of receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone metabolism, immune system and arterial calcification and discuss their potential in the treatment of these diseases.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 50 条
  • [31] RANK and RANK ligand expression in primary human osteosarcoma
    Branstetter, Daniel
    Rohrbach, Kathy
    Huang, Li-Ya
    Soriano, Rosalia
    Tometsko, Mark
    Blake, Michelle
    Jacob, Allison P.
    Dougall, William C.
    JOURNAL OF BONE ONCOLOGY, 2015, 4 (03) : 59 - 68
  • [32] OPG, RANK and RANK ligand expression in thyroid lesions
    Heymann, M.
    Riet, A.
    Battaglia, S.
    Paineau, J.
    Heymann, D.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S64 - S64
  • [33] RANK/RANK ligand/OPG system in the formation of osteoporosis
    Schett, G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 29 - 29
  • [34] OPG, RANK and RANK ligand expression in thyroid lesions
    Heymann, Marie-Francoise
    Riet, Anne
    Le Goff, Benoit
    Battaglia, Severine
    Paineau, Jacques
    Heymann, Dominique
    REGULATORY PEPTIDES, 2008, 148 (1-3) : 46 - 53
  • [35] RANK and RANK Ligand Expression in Parotid Gland Carcinomas
    Franchi, Alessandro
    Taverna, Cecilia
    Simoni, Antonella
    Pepi, Monica
    Mannelli, Giuditta
    Fasolati, Martina
    Gallo, Oreste
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (07) : 478 - 482
  • [36] RANK, RANKL and osteoprotegerin in bone biology and disease
    Wright H.L.
    McCarthy H.S.
    Middleton J.
    Marshall M.J.
    Current Reviews in Musculoskeletal Medicine, 2009, 2 (1) : 56 - 64
  • [37] RANK, RANKL and osteoprotegerin in arthritic bone loss
    Bezerra, MC
    Carvalho, JF
    Prokopowitsch, AS
    Pereira, RMR
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2005, 38 (02) : 161 - 170
  • [38] Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins
    Abrahamsen, B
    Hjelmborg, JV
    Kostenuik, P
    Stilgren, LS
    Kyvik, K
    Adamu, S
    Brixen, K
    Langdahl, BL
    BONE, 2005, 36 (04) : 727 - 735
  • [39] Prostatic Acid Phosphatase in Prostate Cancer Bone Metastases: RANK Ligand and Osteoprotegerin as Mediators.
    Liao, G. V.
    Kirschenbaum, A.
    Yao, S.
    Leiter, A.
    Levine, A. C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 : S90 - S90
  • [40] Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis
    D. Fernández-García
    M. Muñoz-Torres
    P. Mezquita-Raya
    M. de la Higuera
    G. Alonso
    R. Reyes-García
    A. Sebastian Ochoa
    M. E. Ruiz-Requena
    J. Dios Luna
    F. Escobar-Jiménez
    Journal of Endocrinological Investigation, 2008, 31 : 416 - 421